Evidence map›Paper›PMID 41503832›Full record

ReviewCytoskeleton (Hoboken, N.J.)2026

Mitochondria and the Actin Cytoskeleton in Neurodegeneration.

Shivani Tuli, Preet Patel, Aneri Shethji, David Gau

Abstract readReview
In one paragraph

Review in Cytoskeleton (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shivani TuliDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0009-0004-2045-2466
Preet PatelMedia Arts and Sciences, MIT, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0009-0000-8562-2017
Aneri ShethjiDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0009-0007-4566-8281
David GauDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-3079-3692

Funding

NRSA Training CoreTL1TR001858 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RADOMSKI, THOMAS, RUBIO, DORIS M · 2016 to 2025
$11.1M
Profilin as a Novel Target for Vascular Normalization in Renal CancerR00CA267180 · NCI · UNIVERSITY OF TEXAS DALLAS · PI David Martin Gau · 2024 to 2026
$747k
NCI NIH HHS R00 CA267180NIH HHS CA267180NIH HHS TL1 TR001858
6 · The paper itself

Abstract

Mitochondrial dysfunction and cytoskeletal disorganization are widely recognized hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Although these disorders differ in clinical presentation and etiology, accumulating evidence points to a shared cellular vulnerability at the intersection of mitochondrial dynamics and actin cytoskeletal regulation. In this review, we examine the emerging role of actin-mitochondria crosstalk as a convergent mechanism in neurodegeneration. We discuss how disruptions in actin filament remodeling, mitochondrial fission and fusion, organelle transport, and mitophagy contribute to neuronal dysfunction and loss across these diseases. Particular attention is given to disease-specific pathways, including cofilin-actin rod formation in AD, α-synuclein-driven actin disruption in PD, mutant huntingtin's effects on mitochondrial fragmentation in HD, and profilin-1-associated mitochondrial defects in ALS. By synthesizing findings from diverse models, we highlight how perturbations in the cytoskeleton-mitochondria interface may act as an upstream trigger and amplifier of neurodegenerative cascades. We also outline key knowledge gaps and propose future directions for research, with an emphasis on targeting actin-mitochondrial interactions as a potential therapeutic strategy across multiple neurodegenerative conditions.

Indexed as

Actin CytoskeletonMitochondriaNeurodegenerative DiseasesAnimalsHumansMitochondrial Dynamicsactin cytoskeletonmitochondria‐cytoskeleton crosstalkmitochondria dysfunctionneurodegeneration

Identifiers

PMID41503832
PMCPMC13080061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.